1. Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response
   Brittany P. Rickard et al, 2021, Cancers CrossRef
2. Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations
   Amy H. Lee et al, 2022, Cancers CrossRef
3. Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer
   Q H Miow et al, 2015, Oncogene CrossRef
4. Sema4C mediates EMT inducing chemotherapeutic resistance of miR-31-3p in cervical cancer cells
   Li Jing et al, 2019, Scientific Reports CrossRef
5. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line
   Yaman Alghamian et al, 2022, Scientific Reports CrossRef
6. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
   Jharna Datta et al, 2017, Molecular Cancer Therapeutics CrossRef
7. Ampelopsin reduces the migration and invasion of ovarian cancer cells via inhibition of epithelial-to-mesenchymal transition
   TIANFENG LIU et al, 2015, Oncology Reports CrossRef
8. Paclitaxel-loaded polymeric depots as injectable drug delivery system for cancer chemotherapy of hepatocellular carcinoma
   Norased Nasongkla et al, 2017, Pharmaceutical Development and Technology CrossRef
9. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer
   Junli Deng et al, 2016, Oncotarget CrossRef
10. Inactivation of transforming growth factor-β-activated kinase 1 promotes taxol efficacy in ovarian cancer cells
    Li Bo et al, 2016, Biomedicine & Pharmacotherapy CrossRef
11. All‐trans retinoic acid reverses epithelial‐mesenchymal transition in paclitaxel‐resistant cells by inhibiting nuclear factor kappa B and upregulating gap junctions
    Guiling Shi et al, 2019, Cancer Science CrossRef
12. MicroRNAs and Drug Resistance in Prostate Cancers
    Feng Li et al, 2014, Molecular Pharmaceutics CrossRef
13. Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells
    Q Yang et al, 2014, British Journal of Cancer CrossRef
14. Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1
    Denis Soulières et al, 2018, Clinical Cancer Research CrossRef
15. EDIL3 promotes epithelial–mesenchymal transition and paclitaxel resistance through its interaction with integrin αVβ3 in cancer cells
    J. Gasca et al, 2020, Cell Death Discovery CrossRef
16. miR‐25‐3p reverses epithelial‐mesenchymal transition via targeting Sema4C in cisplatin‐resistance cervical cancer cells
    Jing Song et al, 2017, Cancer Science CrossRef
17. Skp2 Regulates the Expression of MMP-2 and MMP-9, and Enhances the Invasion Potential of Oral Squamous Cell Carcinoma
    Shin-ichi Yamada et al, 2016, Pathology & Oncology Research CrossRef
18. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells
    Qingling Yang et al, 2015, Oncotarget CrossRef
19. Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
    Yeong Gyu Jeong et al, 2023, Cancers CrossRef
20. Specific c-Jun N-Terminal Kinase Inhibitor, JNK-IN-8 Suppresses Mesenchymal Profile of PTX-Resistant MCF-7 Cells through Modulating PI3K/Akt, MAPK and Wnt Signaling Pathways
    Pelin Ozfiliz Kilbas et al, 2020, Biology CrossRef
21. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance
    Fang-fang Zhang et al, 2014, European Journal of Pharmacology CrossRef
22. Methylation of Notch3 modulates chemoresistance via P-glycoprotein
    Xiaoting Gu et al, 2016, European Journal of Pharmacology CrossRef
23. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway
    Weiguo Cao et al, 2014, Tumor Biology CrossRef
24. Dual Effects of Non-Coding RNAs (ncRNAs) in Cancer Stem Cell Biology
    Athina A. Kyriazi et al, 2020, International Journal of Molecular Sciences CrossRef
25. β-Catenin expression is regulated by an IRES-dependent mechanism and stimulated by paclitaxel in human ovarian cancer cells
    Qianyun Fu et al, 2015, Biochemical and Biophysical Research Communications CrossRef
26. Epithelial‐to‐Mesenchymal Transition in Paclitaxel‐Resistant Ovarian Cancer Cells Is Downregulated by Luteolin
    Vermont P Dia et al, 2017, Journal of Cellular Physiology CrossRef
27. Resveratrol Inhibits Cisplatin-Induced Epithelial-to-Mesenchymal Transition in Ovarian Cancer Cell Lines
    Sébastien Baribeau et al, 2014, PLoS ONE CrossRef
28. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities
    Milad Ashrafizadeh et al, 2021, Biomedicine & Pharmacotherapy CrossRef
29. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors
    Jordi Rodon et al, 2018, Oncotarget CrossRef
30. Combination of Immune-Related Genomic Alterations Reveals Immune Characterization and Prediction of Different Prognostic Risks in Ovarian Cancer
    Xibo Zhao et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
31. Mechanisms of cancer cell death induction by paclitaxel: an updated review
    Shuang Zhao et al, 2022, Apoptosis CrossRef
32. The therapeutic potential of targeting the epithelial–mesenchymal transition in cancer
    Kevin R Ginnebaugh et al, 2014, Expert Opinion on Therapeutic Targets CrossRef
33. Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells
    Yao-Min Chen et al, 2016, Tumor Biology CrossRef
34. LncRNAs and their role in cancer stem cells
    Shusen Chen et al, 2017, Oncotarget CrossRef
35. Mechanisms of chemoresistance and approaches to overcome its impact in gynecologic cancers
    Nirupama Sabnis et al, 2021, Overcoming Drug Resistance in Gynecologic Cancers CrossRef
36. Nanoparticle delivery systems to combat drug resistance in ovarian cancer
    Emily M. Miller et al, 2021, Nanomedicine: Nanotechnology, Biology and Medicine CrossRef
37. The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism
    Qing-Ling Yang et al, 2017, Oncotarget CrossRef
38. Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer
    Jing Jing Liu et al, 2019, International Journal of Molecular Sciences CrossRef
39. The role of photodynamic therapy in overcoming cancer drug resistance
    Bryan Q. Spring et al, 2015, Photochemical & Photobiological Sciences CrossRef